Antibody Analytics
The Collaborative immunology CRO
Enriching your team
We can tell your molecule’s story
Our mission is to unlock discoveries and develop solutions for biopharmaceutical companies seeking to overcome substantial scientific challenges by providing data of outstanding quality
Meet us in person at upcoming events
We’re so pleased to announce that in 2023 we’ll be exhibiting and presenting at two prestigious conferences:
- PEGS Boston: 15-19th May – stand 125
- Immuno-Oncology Summit Europe in London: 20-22nd June – stand 7
Upcoming webinar
Register for our webinar to hear directly from our CSO, Dr. Agapitos Patakas on the topic of T cell exhaustion and modelling this in cell-based assays.
- Title: Modeling the tumor microenvironment: An in vitro T cell exhaustion model for the characterisation of multi-specific biologics and immunotherapies
- Date: 28th March at 16:00 GMT / 17:00 CET / 11:00 EST / 08:00 PST
- In collaboration with Agilent Technologies
News
Read our latest news and browse our scientific resource articles
25.01.23
5 min read
Antibody Analytics shortlisted for innovation in Pharma Services and Drug Discovery award
Antibody Analytics is thrilled to announce that we have been shortlisted in Scotland's Life Sciences Annual Awards in the 'Innovation Pharma Services and Drug Discovery' category.
04.11.22
5 min read
Treg function, Treg suppression and your therapeutic candidate
Our Treg suppression assay formats are adaptable, using natural Tregs isolated from PBMCs, or induced Tregs expanded and differentiated from naïve CD4+ T cells.
20.10.22
7 min read
T cell exhaustion models for the investigation of checkpoint inhibitors
Antibody Analytics has established an in vitro T cell exhaustion model that can be used to assess candidate immunotherapeutics. Find out more about our unique approach.
19.10.22
5 min read
Best practices in cell line development
Target cells are a critical component of immune cell effector assays. Whether investigating T cell dependent cellular cytotoxicity (TDCC) or antibody dependent cellular cytotoxicity (ADCC), we create engineered target cells uniquely suited for the evaluation of effector function and molecule specificity. But how do we achieve this and what are the principles we follow?